A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men

Article English OPEN
Van Damme, Pierre; Meijer, Chris J. L. M.; Kieninger, Dorothee; Schuyleman, Anne; Thomas, Stephane; Luxembourg, Alain; Baudin, Martine;
  • Publisher: Elsevier BV
  • Journal: Vaccine,volume 34,issue 35,pages4,205-4,212 (issn: 0264-410X)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1016/j.vaccine.2016.06.056
  • Subject: Nine-valent human papilloma virus vaccine | veterinary(all) | Immunology and Microbiology(all) | Safety | Infectious Diseases | Molecular Medicine | Human papilloma virus | Anogenital cancers | Immunogenicity | Human medicine | Anogenital warts | Public Health, Environmental and Occupational Health

Abstract: Background: A nine-valent human papilloma virus (9vHPV) vaccine has been developed to prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV (qHPV) vaccine) as well as to five additional oncogenic HPV types (HPV 31/33/4... View more
Share - Bookmark